EUVIMEDEUVIMED entdecken
VergleichsstudieLeitlinieOpen Access · CC BY-NC-ND 4.0

Comparison of pharmacogenomic guidance in Australian prescribing resources and international pharmacogenomic guidelines

Ruby Soueid iD, Jackson L A Thomas, Luke B Hesson iD, Stephen Hughes iD, Sophie L Stocker iD

Internal Medicine Journal · 2026

DOI: 10.1111/imj.70538 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Internal Medicine Journal, 2026. Verfasst von Ruby Soueid und 4 weiteren Autor:innen. Beteiligte Einrichtung: Sydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia. Hauptthemen laut MEDLINE: Pharmacogenetics, Practice Guidelines as Topic, Pharmacogenomic Testing, Drug Prescriptions. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Ross Brown Scholarship in Pharmacy, Genomics Health Futures Mission.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Pharmacogenomic‐guided medication management optimises drug therapy to enhance patient outcomes. Despite clinical utility, implementation in Australia remains limited, partly due to the lack of clear and consistent guidance.

Aim

This study evaluated the presence and consistency of pharmacogenomic testing indication categories and therapeutic recommendations between Australian prescribing resources and international pharmacogenomic guidelines.

Methods

Testing indications were compared between Dutch Pharmacogenetics Working Group (DPWG), Royal College of Pathologists of Australasia (RCPA) and Australian prescribing resources (Australian Medicines Handbook (AMH), Therapeutic Guidelines (TG), Therapeutics Goods Administration (TGA) and eviQ). Therapeutic recommendations were compared between Clinical Pharmacogenetics Implementation Consortium (CPIC), DPWG, and Australian prescribing resources. Weighted kappa was used for analysis (n > 10) and interpreted using the Landis and Koch scale.

Results

Among Australian resources, AMH included the highest proportion of testing indications (28%, 19/67); however, it remains an overall low proportion. Testing indications were most consistent between RCPA and TG, with 50% (5/10, 95% CI 0.19–0.81) concordant (e.g. mercaptopurine/ TPMT testing ‘recommended’ in both). For therapeutic recommendations, AMH demonstrated substantial agreement with DPWG (κ 0.80, 95% CI 0.61–0.98); however, 11% (3/27) of recommendations were discordant (e.g. capecitabine/ DPYD deficiency ‘dose adjustment’ in DPWG and ‘contraindication’ in AMH). Within Australian resources, most (88%, 7/8, 95% CI 0.47–1.00) testing indications were concordant, while for therapeutic recommendations, just over half (57%, 4/7, 95% CI 0.18–0.90) were concordant.

Conclusions

Australian prescribing resources contain limited and inconsistent pharmacogenomic information. Greater harmonisation is needed to support decision‐making and facilitate broader pharmacogenomic implementation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PharmacogeneticsPractice Guidelines as TopicPharmacogenomic TestingDrug PrescriptionsHumansAustralia

Stichwörter der Autor:innen

consistencyconsistentindicationspharmacogenomicsrecommendations

Autor:innen und Institutionen

  • Sydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
  • Department of Genetics, Douglass Hanly Moir Pathology, Sydney, New South Wales, Australia.
  • School of Life Sciences, Faculty of Science, University of Technology Sydney, Sydney, New South Wales, Australia.
  • Faculty of Medicine, St. Vincent's Clinical Campus, University of New South Wales, Sydney, New South Wales, Australia.
  • Department of Clinical Pharmacology and Toxicology, St. Vincent's Hospital, Sydney, New South Wales, Australia.

ORCID-Profile: Ruby Soueid, Luke B Hesson, Stephen Hughes, Sophie L Stocker

Förderung

  • Ross Brown Scholarship in Pharmacy
  • Genomics Health Futures Mission

Zitieren

APA

Soueid, R., Thomas, J. L. A., Hesson, L. B., Hughes, S., & Stocker, S. L. (2026). Comparison of pharmacogenomic guidance in Australian prescribing resources and international pharmacogenomic guidelines. Internal Medicine Journal. https://doi.org/10.1111/imj.70538

Vancouver

Soueid R, Thomas JLA, Hesson LB, Hughes S, Stocker SL. Comparison of pharmacogenomic guidance in Australian prescribing resources and international pharmacogenomic guidelines. Internal Medicine Journal. 2026. doi:10.1111/imj.70538

BibTeX
@article{Soueid2026,
  author = {Soueid, Ruby and Thomas, Jackson L A and Hesson, Luke B and Hughes, Stephen and Stocker, Sophie L},
  title = {Comparison of pharmacogenomic guidance in Australian prescribing resources and international pharmacogenomic guidelines},
  journal = {Internal Medicine Journal},
  year = {2026},
  doi = {10.1111/imj.70538}
}
Kostenlos starten →